This new position paper supplements the 320-page report entitled “The French Pharma Market 2022 – 2027 – Strategic Implications for Pharma companies” that we have released earlier this month (click on the following links to have access to the report excerpts and the order form).
Smart Pharma Consulting has evaluated the France’s attractiveness for pharma companies – by comparison with Germany, Italy, UK and Spain – through four key dimensions:
… and made recommendations to enhance it.
Best regards,